Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.48 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435663 | 0.90 | KDM4E (0.59) | KDM4EALDH1A1PKMPTGER1NPC1 | |
| SCHEMBL438096 | 0.86 | KDM4E (0.55) | KDM4EALDH1A1PKMPTGER1SETD7 | |
| SCHEMBL436574 | 0.80 | ALDH1A1 (0.55) | KDM4EALDH1A1PKMPTGER1NPC1 | |
| SCHEMBL436597 | 0.78 | ALDH1A1 (0.55) | KDM4EALDH1A1PKMPTGER1NPC1 | |
| SCHEMBL2998645 | 0.75 | KDM4E (0.51) | KDM4EALDH1A1PKMPTGER1ENPP2 | |
| SCHEMBL437676 | 0.75 | ALDH1A1 (0.67) | KDM4EALDH1A1PKMPTGER1NPC1 | |
| SCHEMBL2986715 | 0.73 | PTGER1 (0.44) | KDM4EALDH1A1PKMPTGER1SETD7 | |
| SCHEMBL435628 | 0.73 | PLA2G10 (0.48) | KDM4EALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL2993392 | 0.72 | MAPT (0.45) | KDM4EALDH1A1PKMPTGER1SETD7 | |
| SCHEMBL436569 | 0.72 | ALDH1A1 (0.59) | KDM4EALDH1A1PKMPTGER1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | KDM4E 3824/4885ALDH1A1 2759/4885PKM 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.